Antiviral alternatives against important members of the subfamily Parvovirinae: a review

Arch Virol. 2024 Feb 20;169(3):52. doi: 10.1007/s00705-024-05995-8.

Abstract

Parvoviruses are responsible for multiple diseases, and there is a critical need for effective antiviral therapies. Specific antiviral treatments for parvovirus infections are currently lacking, and the available options are mostly supportive and symptomatic. In recent years, significant research efforts have been directed toward understanding the molecular mechanisms of parvovirus replication and identifying potential targets for antiviral interventions. This review highlights the structure, pathogenesis, and treatment options for major viruses of the subfamily Parvovirinae, such as parvovirus B19 (B19V), canine parvovirus type 2 (CPV-2), and porcine parvovirus (PPV) and also describes different approaches in the development of antiviral alternatives against parvovirus, including drug repurposing, serendipity, and computational tools (molecular docking and artificial intelligence) in drug discovery. These advances greatly increase the likelihood of discoveries that will lead to potent antiviral strategies against different parvovirus infections.

Keywords: Treatments; canine parvovirus; parvovirus B19; pathogenesis; porcine parvovirus.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Artificial Intelligence
  • Molecular Docking Simulation
  • Parvoviridae Infections* / drug therapy
  • Parvovirinae*
  • Parvovirus B19, Human*
  • Parvovirus*
  • Swine

Substances

  • Antiviral Agents